Table 2.
Functional tests, gait parameters, and drug treatments a.
| All patients (n = 160) | Nonfallers (n = 98) | Fallers (n = 62) | Testb | P value | |
|---|---|---|---|---|---|
| Tinetti | |||||
| Balance | 10.9 (5.7) | 13.4 (3.9) | 7.1 (6.0) | 1 | <0.001 |
| Gait | 8.6 (4,6) | 10.3 (3.2) | 5.8 (5.2) | 1 | <0.001 |
| Total | 19.5 (10.2) | 23.7 (7.0) | 12.9 (11.0) | 1 | <0.001 |
| Timed up and go (s) | 11.4 (8.0) | 10.7 (7.9) | 13.1 (8.1) | 1 | 0.004 |
| Velocity (m/s) | 1.17 (0.31) | 1.19 (0.30) | 1.10 (0.32) | 1 | 0.293 |
| Step length (m) | 0.77 (0.20) | 0.79 (0,24) | 0.69 (0.22) | 1 | 0.093 |
| Cadence (steps/s) | 1.55 (0.70) | 1.52 (0.23) | 1.61 (0.41) | 1 | 0.253 |
| Levodopa use (n, %) | 139 (86.8) | 84 (85.7) | 55 (88.7) | 2 | 0.639 |
| Levodopa dose (mg/d) | 557.8 (254.1) | 504.1 (208.3) | 638.7 (295.8) | 1 | 0.005 |
| Dopamine agonist use (n, %) | 98 (61.2) | 58 (59.2) | 40 (64.5) | 2 | 0.511 |
| MAOB-I use (n, %) | 49 (30.6) | 29 (29.5) | 20 (32.2) | 2 | 0.728 |
| COMT-I use (n, %) | 25 (15.6) | 10 (10.2) | 15 (24.2) | 2 | 0.025 |
| Amantadine use (n, %) | 13 (8,1) | 5 (5.1) | 8 (12.9) | 2 | 0.134 |
| Anticholinergic use (n, %) | 2 (1.2) | 2 (2.0) | 0 | ||
| Polytherapy (n, %) | 83 (51.8) | 49 (50.0) | 34 (54.8) | 2 | 0.649 |
| Benzodiazepine use (n, %) | 22 (13.7) | 12 (12.2) | 10 (16.1) | 2 | 0.490 |
| Antidepressant use (n, %) | 18 (11.2) | 11 (11.2) | 7 (11.3) | 2 | 1.000 |
| Neuroleptic use (n, %) | 8 (5.0) | 1 (1.0) | 7 (11.3) | 2 | 0.006 |
| Cholinesterase inhibitor use (n, %) | 7 (4.3) | 0 | 7 (11.3) | 2 | 0.001 |
Abbreviations. MAOBI: inhibitor of monoamine oxidase B; COMTI: inhibitor of catechol-O-methyl transferase.
aData are mean(SD), absolute numbers, or percentage.
bTest 1 = independent samples t-test; test 2 = χ 2 test.